Free tool
FAERS Monitor: Inlexzo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219683 or its brand name (Inlexzo, Gemcitabine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
484
Serious
108
22% of reports
Hospitalization
37
Death reported
5
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pollakiuria96
- dysuria94
- micturition urgency52
- urinary tract infection45
- bladder pain38
- bladder spasm31
- haematuria27
- drug intolerance25
- pain22
- product dose omission issue19
- lower urinary tract symptoms18
- adverse event15
- device dislocation15
- urinary incontinence14
- bladder irritation12
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 26 |
| 2026 | 458 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,675 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| lower urinary tract symptomsSignal | 18 | 2276.1 | 1429.1 | 36,768 |
| bladder irritationSignal | 12 | 828.6 | 471.3 | 8,938 |
| bladder spasmSignal | 31 | 731.7 | 518.9 | 21,535 |
| bladder painSignal | 38 | 526.4 | 387.2 | 19,177 |
| micturition urgencySignal | 52 | 198.7 | 153.6 | 9,993 |
| dysuriaSignal | 94 | 111.3 | 92.8 | 10,153 |
| pollakiuriaSignal | 96 | 100.3 | 83.8 | 9,333 |
| haematuriaSignal | 27 | 34.3 | 23.8 | 840 |
| urinary incontinenceSignal | 14 | 20.5 | 12.3 | 241 |
| device dislocationSignal | 15 | 15.0 | 9.1 | 183 |
| urinary tract infectionSignal | 45 | 11.5 | 8.7 | 423 |
| drug intoleranceSignal | 25 | 11.2 | 7.7 | 224 |
| adverse eventSignal | 15 | 7.1 | 4.3 | 73 |
| product dose omission issueSignal | 19 | 2.8 | 1.8 | 21 |
| pain | 22 | 1.6 | 1.0 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.